Transcription of Therapeutic Class Overview Benign Prostatic …
{{id}} {{{paragraph}}}
Example: dental hygienist
Therapeutic Class Overview Benign Prostatic …
Page 1 o f 6 Copyright 2014 Review Completed on 09/ 22/2014 Therapeutic Class Overview Benign Prostatic Hyperplasia Treatments Therapeutic Class Overview /Summary: The agents approved for the treatment of signs and symptoms of benignprostatic hyperplasia will be the focus of this review. The -adrenergic blockers including, alfuzosin,doxazosin, silodosin, tamsulosin, and terazosin, reduce smooth-muscle tone in the prostate andbladder neck decreasing lower urinary tract symptoms (LUTS) secondary to BPH. Alfuzosin, silodosinand tamsulosin are selective to the -adrenergic receptors located in the prostate and therefore areonly Food and Drug Administration (FDA) approved for BPH, whereas doxazosin and terazosinadditionally inhibit -adrenergic receptors found in the vascular smooth muscle and are additionallyindicated for The 5- reductase inhibitors, dutasteride and finasteride, are appropriatetreatment options for LUTS associated with overall Prostatic enlargement.
†In men with an enlarged prostate, to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: